We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focuse...
Stemline Therapeutics, Inc. is a commercial-sta...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Ionis is a sustainably profitable, multi-product company with a pipeline of more t...
Ionis is a sustainably profitable, multi-produc...
Allakos is a clinical-stage company developing therapeutic antibodies that selecti...
Allakos is a clinical-stage company developing ...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
Join the National Investor Network and get the latest information with your interests in mind.